Skip to main content

Peer Review reports

From: Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor

Original Submission
14 Oct 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
23 Dec 2021 Reviewed Reviewer Report
28 Dec 2021 Reviewed Reviewer Report
11 Feb 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 3
11 Feb 2022 Submitted Manuscript version 3
18 Apr 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 4
18 Apr 2022 Submitted Manuscript version 4
19 Apr 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 5
19 Apr 2022 Submitted Manuscript version 5
25 May 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 6
25 May 2022 Submitted Manuscript version 6
28 May 2022 Reviewed Reviewer Report
29 Jun 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 7
29 Jun 2022 Submitted Manuscript version 7
14 Jul 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 8
14 Jul 2022 Submitted Manuscript version 8
19 Jul 2022 Author responded Author comments - Daniela Romina Montagna
Resubmission - Version 9
19 Jul 2022 Submitted Manuscript version 9
Publishing
26 Jul 2022 Editorially accepted
3 Aug 2022 Article published 10.1186/s12885-022-09941-2

You can find further information about peer review here.

Back to article page